Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2009

View Archived Issues

Glutamate receptor antagonists have beneficial effects in model of Batten disease / News in Context

Phase III trials show improved sleep maintenance with doxepin

Phase I and II studies find Quadramet-docetaxel combination safe, active in prostate cancer

Alcon discontinues development of anecortave acetate in IOP after phase II trial

Phase II and III studies detail Acurox tolerability and analgesic efficacy

Full study results show OGX-011 meets requirements for further evaluation in prostate cancer

Celgene files NDA in Japan for Revlimid for multiple myeloma

Revotar to initiate phase IIa study of bimosiamose

FDA reviews Oxford Biomedica's phase III TRIST study of TroVax in renal cancer

Spectrum receives complete response letter from the FDA for Zevalin sBLA in NHL

Allos completes recruitment into phase IIb clinical trial of pralatrexate in advanced NSCLC

Novel guanylate cyclase activators emerge from GlaxoSmithKline R&D

Novel radiosensitizers claimed by K. Marcinkowski University of Medical Sciences

Palau Pharma patents histamine H4 receptor antagonists

ZSTK-474 inhibits angiogenesis in vitro and in vivo

Phase II data on ASA-404 in non-small cell lung cancer published

GTx initiates phase I clinical trial of GTx-758 for advanced prostate cancer

Pharmasset nominates PSI-938 as development candidate for HCV infection

Lexicon begins phase II clinical trial of LX-1032 in carcinoid syndrome

Repros provides update on clinical development of Proellex

Rexahn completes enrollment in phase IIa clinical trial of Serdaxin in MDD

FDA and King meet to discuss complete response letter regarding NDA for Remoxy

Inhibiton Therapeutics changes name to AlumiFuel Power

Kineta acquires exclusive commercial rights to Airmid's portfolio of therapeutic compounds

Presidio advances HCV inhibitor PPI-461 toward clinical development, IND-enabling studies under way

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...